Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)
Corral, Julieta (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Espinàs, Josep Alfons (Institut d'Investigació Biomèdica de Bellvitge)
Cots Reguant, Francesc (Parc de Salut MAR de Barcelona)
Pareja, Laura (Institut d'Investigació Biomèdica de Bellvitge)
Solà, Judit (Institut d'Investigació Biomèdica de Bellvitge)
Font, Rebeca (Institut d'Investigació Biomèdica de Bellvitge)
Borras, Josep M (Universitat de Barcelona. Departament de Ciències Clíniques)

Data:	2015
Resum:	Assessing of the costs of treating disease is necessary to demonstrate cost-effectiveness and to estimate the budget impact of new interventions and therapeutic innovations. However, there are few comprehensive studies on resource use and costs associated with lung cancer patients in clinical practice in Spain or internationally. The aim of this paper was to assess the hospital cost associated with lung cancer diagnosis and treatment by histology, type of cost and stage at diagnosis in the Spanish National Health Service. A retrospective, descriptive analysis on resource use and a direct medical cost analysis were performed. Resource utilisation data were collected by means of patient files from nine teaching hospitals. From a hospital budget impact perspective, the aggregate and mean costs per patient were calculated over the first three years following diagnosis or up to death. Both aggregate and mean costs per patient were analysed by histology, stage at diagnosis and cost type. A total of 232 cases of lung cancer were analysed, of which 74. 1% corresponded to non-small cell lung cancer (NSCLC) and 11. 2% to small cell lung cancer (SCLC); 14. 7% had no cytohistologic confirmation. The mean cost per patient in NSCLC ranged from 13,218 Euros in Stage III to 16,120 Euros in Stage II. The main cost components were chemotherapy (29. 5%) and surgery (22. 8%). Advanced disease stages were associated with a decrease in the relative weight of surgical and inpatient care costs but an increase in chemotherapy costs. In SCLC patients, the mean cost per patient was 15,418 Euros for limited disease and 12,482 Euros for extensive disease. The main cost components were chemotherapy (36. 1%) and other inpatient costs (28. 7%). In both groups, the Kruskall-Wallis test did not show statistically significant differences in mean cost per patient between stages. This study provides the costs of lung cancer treatment based on patient file reviews, with chemotherapy and surgery accounting for the major components of costs. This cost analysis is a baseline study that will provide a useful source of information for future studies on cost-effectiveness and on the budget impact of different therapeutic innovations in Spain.
Ajuts:	Instituto de Salud Carlos III RD12-0036-0053
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cancer ; Costs ; Hospital costs ; Lung cancer ; Non-small cell lung cancer (NSCLC) ; Small cell lung cancer (SCLC)
Publicat a:	BMC health services research, Vol. 15 (february 2015) , ISSN 1472-6963

DOI: 10.1186/s12913-015-0725-3
PMID: 25889153

10 p, 361.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats